Concepedia

Efficacy and safety of the novel glycine transporter inhibitor BI 425809 once daily in patients with schizophrenia: a double-blind, randomised, placebo-controlled phase 2 study

W. Wolfgang Fleischhacker, Jana Podhorná, Martina Gröschl, Sanjay Hake, Songqiao Huang, Richard S.E. Keefe, Michael Desch, Ronald Brenner, David P. Walling, E. Mantero-Atienza,

The Lancet Psychiatry · 2021 · 134 citations · 27 references

DOI

Concepts

References

27

A Summary of the FDA-NIMH-MATRICS Workshop on Clinical Trial Design for Neurocognitive Drugs for Schizophrenia

R. W. Buchanan · Schizophrenia Bulletin · 2005 · 437 citations · Full text

, , +17

Defining a cognitive function decrement in schizophrenia

Richard S.E. Keefe, Charles E. Eesley, Margaret P. Poe · Biological Psychiatry · 2005 · 392 citations

, , +12

The MCCB impairment profile for schizophrenia outpatients: Results from the MATRICS psychometric and standardization study

Robert S Kern, James M. Gold, Dwight Dickinson et al. · Schizophrenia Research · 2010 · 252 citations

, , +17

Effect of Bitopertin, a Glycine Reuptake Inhibitor, on Negative Symptoms of Schizophrenia

Daniel Umbricht, Daniela Alberati, Meret Martin‐Facklam et al. · JAMA Psychiatry · 2014 · 230 citations

, , +16

Determinants of different aspects of everyday outcome in schizophrenia: The roles of negative symptoms, cognition, and functional capacity

Martin Strassnig, Tenko Raykov, Cedric O’Gorman et al. · Schizophrenia Research · 2015 · 175 citations · Full text

, , +17